
==== Front
eLife
Elife
eLife
eLife
2050-084X
eLife Sciences Publications, Ltd

39291958
96790
10.7554/eLife.96790
version of record
Research Article
Immunology and Inflammation
The common Sting1 HAQ, AQ alleles rescue CD4 T cellpenia, restore T-regs, and prevent SAVI (N153S) inflammatory disease in mice
Aybar-Torres Alexandra a 1
Saldarriaga Lennon A 1
Pham Ann T 1
Emtiazjoo Amir M 1
Sharma Ashish K 2
Bryant Andrew j 1
Jin Lei https://orcid.org/0000-0001-6836-1142
lei.jin@medicine.ufl.edu
1
1 https://ror.org/02y3ad647 Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida Gainesville United States
2 https://ror.org/02y3ad647 Division of Vascular Surgery & Endovascular Therapy, Department of Surgery, University of Florida Gainesville United States
Rothlin Carla V Reviewing Editor https://ror.org/03v76x132 Yale University United States

Rothlin Carla V Senior Editor https://ror.org/03v76x132 Yale University United States

18 9 2024
2024
13 RP9679024 3 2024
This manuscript was published as a preprint.24 3 2024

This manuscript was published as a reviewed preprint.13 6 2024

The reviewed preprint was revised.19 8 2024

© 2024, Aybar-Torres et al
2024
Aybar-Torres et al
https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

The significance of STING1 gene in tissue inflammation and cancer immunotherapy has been increasingly recognized. Intriguingly, common human STING1 alleles R71H-G230A-R293Q (HAQ) and G230A-R293Q (AQ) are carried by ~60% of East Asians and ~40% of Africans, respectively. Here, we examine the modulatory effects of HAQ, AQ alleles on STING-associated vasculopathy with onset in infancy (SAVI), an autosomal dominant, fatal inflammatory disease caused by gain-of-function human STING1 mutations. CD4 T cellpenia is evident in SAVI patients and mouse models. Using Sting1 knock-in mice expressing common human STING1 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splenocytes resist STING1-mediated cell death ex vivo, establishing a critical role of STING1 residue 293 in cell death. The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice did not have CD4 T cellpenia. The HAQ/SAVI(N153S), AQ/SAVI(N153S) mice have more (~10-fold, ~20-fold, respectively) T-regs than WT/SAVI(N153S) mice. Remarkably, while they have comparable TBK1, IRF3, and NFκB activation as the WT/SAVI, the AQ/SAVI mice have no tissue inflammation, regular body weight, and normal lifespan. We propose that STING1 activation promotes tissue inflammation by depleting T-regs cells in vivo. Billions of modern humans have the dominant HAQ, AQ alleles. STING1 research and STING1-targeting immunotherapy should consider STING1 heterogeneity in humans.

STING
SAVI
chronic inflammation
regulatory T cells
cell death
T cellpenia
Research organism

Human
Mouse
http://dx.doi.org/10.13039/100000050 National Heart, Lung, and Blood Institute HL152163 Jin Lei The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author impact statementThe common human HAQ,AQ alleles suppress STING1 gain-of-function mutation-induced chronic STING1 inflammation in mice.
publishing-routeprc
==== Body
pmcIntroduction

STING1 drives cytosolic DNA-induced type I IFNs production (Barber, 2015). Recent research revealed that STING1 promotes inflammation in a variety of inflammatory diseases, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, kidney injury, neurodegenerative diseases, cardiovascular diseases, obesity, diabetes, and aging (Skopelja-Gardner et al., 2022; Bai and Liu, 2021; Li et al., 2023; Gulen et al., 2023; Szego et al., 2022; Gao et al., 2023b; Yan et al., 2022; Gao et al., 2023a). The type I IFNs-independent function of STING1 has also emerged (Gao et al., 2023a; Yamashiro et al., 2020; Wu et al., 2020; Pham et al., 2024). For example, initially described as a type I interferonopathy (Liu et al., 2014), recent studies in STING-associated vasculopathy with onset in infancy (SAVI) mouse models showed that SAVI is largely independent of type I IFNs (Luksch et al., 2019; Stinson et al., 2022; Warner et al., 2017; Frémond et al., 2021). In a Sting1 N153S mouse model of SAVI, crossing N153S mice to IRF3/IRF7, and IFNAR1 knockout mice, N153S mice still developed spontaneous lung diseases (Luksch et al., 2019). JAK inhibitors were used to block type I IFNs signaling for SAVI patients with mixed success (Frémond et al., 2021; Kim et al., 2022; Volpi et al., 2019; Tang et al., 2020). For example, in a review of JAK inhibition in 18 SAVI patients, incomplete response to treatment happened in 7/18 (38%) of patients (Dai et al., 2020). Furthermore, two patients died of respiratory failure despite this treatment (Dai et al., 2020). Both radioresistant parenchymal and/or stromal cells and hematopoietic cells influence SAVI pathology in mice (Gao et al., 2024; Gao et al., 2022). The observation is important because it predicts that allogeneic stem cell transplantation may not work in human SAVI patients. Indeed, lung transplantations did not show improvement in SAVI patients (Kim et al., 2022; Picard et al., 2016). Patients died at 3- and 9 months post-lung transplant (Kim et al., 2022; Picard et al., 2016). How STING1 drives inflammation in vivo, independent of type I IFNs, remains unknown. Consequently, SAVI has no curative care.

Characterized as an innate immune sensor, STING1 expression is, paradoxically, high in CD4 T cells (Liu et al., 2014; Jin et al., 2013). Furthermore, STING1 activation kills mouse and human CD4 T cells ex vivo (Larkin et al., 2017; Cerboni et al., 2017; Kuhl et al., 2023). SAVI patients and mouse models had CD4 T cellpenia (Liu et al., 2014; Kuhl et al., 2023). STING1 was first discovered as MPYS for its cell growth inhibition and cell death function in mouse B lymphoma cells (Jin et al., 2008). STING1-mediated cell death is cell type dependent. For example, while STING1 activation kills human endothelial cells, primary and cancerous T cells, it does not kill mouse MEFs, BMDCs, or BMDMs (Gulen et al., 2017; Kabelitz et al., 2022; Murthy et al., 2020). Second, STING1-mediated cell death is type I IFNs-independent (Kuhl et al., 2023; Gulen et al., 2017; Murthy et al., 2020). Multiple cell death pathways, that is apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed (Murthy et al., 2020; Li et al., 2021; Song et al., 2022). Last, the in vivo biological significance of STING1-mediated CD4 T cell death is not clear (Kuhl et al., 2023; Murthy et al., 2020). In humans, SAVI patients with constitutively activated STING1 have low CD4 T cell numbers (Liu et al., 2014), and type I IFNs are dispensable for STING1-mediated human CD4 T cell death (Kuhl et al., 2023). Different from SAVI mice, SAVI patients (N154S or V155M) had normal counts of CD8 T and B cells (Liu et al., 2014).

The human STING1 gene is highly heterogeneous (Jin et al., 2011; Patel et al., 2017a). Approximately 50% of people in the U.S. carry at least one copy of non-WT STING1 allele (Jin et al., 2011). Among them, the R71H-G230A-R293Q (HAQ) is the second most common STING1 allele carried by ~23% of people in the U.S. (Jin et al., 2011). However, in East Asians, WT/HAQ (34.3%), not WT/WT (22.0%), is the most common STING1 genotype (Patel et al., 2017a). Critically, the HAQ allele was positively selected in modern humans outside Africa Mansouri et al., 2022. Anatomically modern humans outside Africa are descendants of a single Out-of-Africa Migration 50,000~70,000 years ago. ~1.4% of Africans have the HAQ allele, while ~63.9% of East Asians are HAQ carriers (Mansouri et al., 2022). Haplotype analysis revealed that HAQ was derived from G230A-R293Q (AQ) allele (Mansouri et al., 2022). Importantly, the AQ allele was negatively selected outside Africa (Mansouri et al., 2022). Approximately 40.1% of Africans are AQ carriers, while ~0.4% of East Asians have the AQ allele (Mansouri et al., 2022). STING1 alleles often have a dominant negative effect likely because the protein STING1 exists as a homodimer (Jin et al., 2008; Patel and Jin, 2019). SAVI is an autosomal dominant inflammatory disease (Liu et al., 2014). WT/HAQ individuals had reduced Pneumovax23-induced antibody responses compared to WT/WT individuals (NCT02471014) (Sebastian et al., 2020). Notably, AQ responds to CDNs and produces type I IFNs in vivo and in vitro (Mansouri et al., 2022; Yi et al., 2013; Patel et al., 2017b), but the AQ allele was negatively selected in non-Africans (Mansouri et al., 2022). In contrast, the HAQ allele, defective in CDNs-type I IFNs responses (Jin et al., 2011; Patel et al., 2017a; Sebastian et al., 2020; Nissen et al., 2018; Ruiz-Moreno et al., 2018), was positively selected in non-Africans (Mansouri et al., 2022), indicating that the CDNs-type I IFNs independent function of STING1 was essential for the survival of early modern humans outside of Africa.

In this study, we discovered, surprisingly, that the HAQ, AQ splenocytes are resistant to STING1-mediated cell death. We generated HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice and found that the HAQ, AQ alleles prevent CD4 T cellpenia, increasing/restoring T-regs and alleviating/stopping tissue inflammation in SAVI mice, thus providing evidence for the in vivo significance of type I IFNs-independent, STING1-mediated cell death and potential AQ-based curative therapy for SAVI patients.

Results

STING1 activation kills mouse spleen CD4, CD8 T, and CD19 B cells ex vivo

We first used the synthetic non-CDNs STING1 agonist diABZI (Ramanjulu et al., 2018) to induce lymphocyte death because diABZI induces cell death without the need for lipid transfection or detergent for cell permeabilization (Kabelitz et al., 2022; Messaoud-Nacer et al., 2022) and diABZI is in clinical trials (NCT05514717). Splenocytes from C57BL/6 N mice were treated with diABZI in culture, and cell death was determined by Annexin V and Propidium Iodide stain. Splenocyte cell death could be detected at 5 hr post diABZI treatment (Figure 1—figure supplement 1A). Dosage responses showed that ~25 ng/ml diABZI could kill 70% of splenocytes (Figure 1—figure supplement 1B). Similarly, STING1 agonists DMXAA and synthetic CDNs RpRpss-Cyclic di-AMP killed mouse spleen CD4, CD8 T cells, and CD19 B cells (Figure 1A). Thus, STING1 activation readily induces mouse lymphocyte death ex vivo.

Figure 1. Splenocytes from HAQ, AQ, and Q293 mice are resistant to STING1-mediated cell death ex vivo.

(A) C57BL/6 N splenocytes were treated directly (no transfection) with diABZI (100 ng/ml), RpRpss-Cyclic di-AMP (5 μg/ml) or 2′3′-cGAMP (10 μg/ml), DMXAA (25 μg/ml) for 24 hr in culture. CD4, CD8 T cells and CD19 B cells death were determined by PI staining. (B). Splenocytes from C57BL/6 N mice were pre-treated with indicated small molecules, GSK2334470 (1.25 µM), GSK8612 (2.5 µM), Bx-795 (0.5 µM), QVD-OPH (25 µM) for 2 hrs. diABZI (100 ng/ml) was added in culture for another 24 hr. Dead cells were determined by PI staining. (C–D). Flowcytometry of HAQ, AQ, IFNAR1-/- or C57BL/6 N splenocytes treated with diABZI (100 ng/ml) for 24 hrs. Cell death was determined by PI staining. (E–F). Q293 or the WT littermates splenocytes were treated with diABZI (100 ng/ml), RpRpss-Cyclic di-AMP (5 μg/ml) or 2′3′-cGAMP 10 μg/ml for 24 hr. Cell death was determined by PI staining. (G). WT/HAQ, WT/AQ, or WT/WT littermates splenocytes were treated with DMXAA (10, 25 or 100 µg/ml) for 24 hr. Cell death was determined by PI staining. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test (A, E, G) or unpaired student T-test (B, D) * p<0.05. n.s: not significant.

Figure 1—figure supplement 1. Bx-795 inhibits diABZI-induced mouse splenocyte death.

(A) Splenocytes from C57BL/6N mice were treated with 100ng/ml diABZI in culture for the indicated time. Dead cells were determined by PI and Annexin V staining. (B) Splenocytes from C57BL/6N mice were treated with indicated dose of diABZi in culture for 24hrs. Dead cells were determined by PI staining. (C) Splenocytes from C57BL/6N mice were pre-treated with indicated small molecules, H151 (10µg/ml), C176 (1µM), MCC950 (1.25µM), 2-BP (20µM), GSK872 (312.5nM), Liproxstatin-1 (1µM), necrostatin-1 (10µM), VX-765 (1µM), Z-DEVD-FMK (25µM), Bx-795 (0.5µM) for 2 hr. diABZi (100ng/ml) was added in culture for another 24 hr. Dead cells were determined by PI staining. (D) IFNβ was determined in the cell supernatant from C by ELISA. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. n=3~5 mice/group. p values are determined by one-way ANOVA Tukey’s multiple comparison test (A, D) or unpaired student T-test (C). * p.

TBK1 activation is required for STING1-mediated mouse spleen cell death ex vivo

STING1 activation can lead to apoptosis, pyroptosis, necroptosis, or ferroptosis (Kuhl et al., 2023; Jin et al., 2008; Gulen et al., 2017; Kabelitz et al., 2022; Murthy et al., 2020; Li et al., 2021; Song et al., 2022; Messaoud-Nacer et al., 2022; Tang et al., 2016). We then treated mouse splenocytes with apoptosis, pyroptosis, necroptosis inhibitors, STING1 inhibitors H-151, C-176, and palmitoylation inhibitor 2-bromopalmitate (2 BP), followed by diABZI stimulation. Inhibitors for NLRP3 (MCC950), RIPK1 (Necrostatin-1), RIPK3 (GSK872), Caspase-1 (VX-795), Caspase-3 (Z-DEVD-FMK), Caspase 1,3,8,9 (Q-VD-Oph), ferroptosis (liproxstatin-1) did not affect diABZI-induced splenocyte cell death ex vivo (Figure 1—figure supplement 1B, C). The STING1 inhibitors H-151, C-176, and 2 BP also could not prevent diABZI-induced cell death (Figure 1—figure supplement 1C), although they inhibited diABZI-induced IFNβ production (Figure 1—figure supplement 1D). Instead, the TBK1 inhibitor BX-795 abolished diABZI-induced splenocyte death (Figure 1—figure supplement 1C).

BX-795 is a multi-kinase inhibitor, including 3-phosphoinositide-dependent protein kinase 1 (PDK1) and TBK1 (IC50s = 6 and 11 nM, respectively). However, the treatment of PDK1 inhibitor GSK2334470 (IC50=10 nM) did not prevent diABZI-induced splenocyte death (Figure 1B). In contrast, GSK8612, a highly potent and selective inhibitor for TBK1, prevented diABZI-induced splenocyte death (Figure 1B). Thus, TBK1 activation is likely critical for STING1-mediated splenocyte cell death ex vivo.

HAQ, AQ, Q293 STING1 knock-in mouse splenocytes are resistant to STING1-mediated cell death ex vivo

HAQ and AQ are common human STING1 alleles (Jin et al., 2011; Patel et al., 2017a; Mansouri et al., 2022). Previously, we reported that HAQ knock-in mice are defective in CDNs-induced immune responses, while CDNs responses in AQ knock-in mice are similar to WT mice (Mansouri et al., 2022). We treated splenocytes from HAQ and AQ mice with diABZI ex vivo and found, surprisingly, that both HAQ and AQ splenocytes were resistant to diABZI-induced cell death (Figure 1C and D). In comparison, IFNAR1-/- splenocytes were killed by diABZI, confirming that STING1-mediated lymphocytes death are type I IFNs-independent (Figure 1C and D; Kuhl et al., 2023; Gulen et al., 2017; Murthy et al., 2020).

HAQ and AQ share the common A230 and Q293 residues changes. We thus generated a Q293 Sting1 knock-in mouse. Notably, the Q293 splenocytes were resistant to STING1 agonists 2’3’-cGAMP, RpRpss-Cyclic di-AMP, and diABZI-induced cell death (Figure 1E and F). Thus, the residue 293 of STING1 is critical for its cell death function.

WT/HAQ, WT/AQ mouse splenocytes are partially resistant to STING1-mediated cell death ex vivo

WT/HAQ (34.3%) is the most common human STING1 genotype in East Asians, while WT/AQ (28.2%) is the 2nd most common STING1 genotype in Africans (Patel et al., 2017a). We generated WT/HAQ, WT/AQ mice and treated their splenocytes with mouse STING1 agonist DMXAA. WT/HAQ and WT/AQ splenocytes were protected from 25 µg/ml DMXAA-induced cell death (Figure 1G). A total of 100 µg/ml DMXAA could kill WT/HAQ and WT/AQ splenocytes, albeit less than WT/WT cells (Figure 1G). Thus, the HAQ and AQ alleles are dominant and likely impact STING1 activation even in heterozygosity.

STING1 activation kills primary human CD4 T cells but not CD8 T or CD19 B cells

STING1 agonists-based clinical trials in humans have been disappointing (NCT02675439, NCT03010176, NCT05514717; Meric-Bernstam et al., 2023; Meric-Bernstam et al., 2022). We showed that the human STING1 gene might undergo natural selection during the out-of-Africa migration (Mansouri et al., 2022) sensitive to evolutionary pressure. Thus, we investigated STING1-mediated death in primary human lymphocytes.

Human explant lung cells from the WT(R232)/WT(R232) donors were treated with STING1 agonists 2’3 c GAMP, RpRpss-Cyclic di-AMP, diABZI for 24 hr in culture. Lymphocyte cell death was determined by Propidium Iodide staining. Different from mouse lymphocytes, diABZI and RpRpss-Cyclic di-AMP killed human CD4 T but not CD8 T or CD19 B cells (Figure 2A and B). Human CD8 T and CD19 B cells are resistant to 500 ng/ml diABZI-induced cell death (Figure 2—figure supplement 1A).

Figure 2. HAQ, AQ, and Q293 human cells are resistant to STING1 agonists-induced death.

(A–B) Total human Lung cells from WT/WT individuals were treated with diABZi (100 ng/ml) for 24 hr. Cell death in CD4, CD8 T cells and CD19 B cells were determined by PI staining. (C). Total lung cells from a WT/HAQ (2 individuals) and a WT/WT (3 individuals) were treated with diABZi (25, 100 ng/ml) for 24 hr. Cell death in CD4 T cells was determined by PI staining. (D–E). STING1-KO THP-1 cells (Invivogen,, cat no. thpd-kostg) were stably reconstituted with human WT (R232), HAQ, AQ, Q293. Cells were treated with diABZI (200 ng/ml) in culture for 24 hr. Dead cells were determined by Annexin V staining. (F). STING1-KO THP-1 cells stably reconstituted with human WT (R232), Q293 were treated with indicated dose of diABZI for 24 hr in culture. Dead cells were determined by Annexin V staining. (G). STING1-KO THP-1 cells stably reconstituted with human WT (R232), Q293 were treated with indicated dose of diABZI for 2hs in culture. STING1 activation was detected by anti-STING1 antibody (Proteintech, #19851–1-AP). (H). STING1-KO THP-1 cells stably reconstituted with human WT (R232), HAQ, AQ, Q293 were treated with 50 ng/ml diABZI in culture for 24 hr. ISG-54 reporter luciferase activity was determined in cell supernatant and normalized to 10 ng/ml IFNβ-stimulated ISG-54 luciferase activity. (I). STING1-KO THP-1 cells stably reconstituted with human WT (R232), HAQ, AQ were treated with 50 ng/ml diABZI in culture for 2 hr. STING1 and IRF3 activation were determined by anti-STING1 antibody and anti-p IRF3 antibody (CST, Ser396, clone 4D4G). Densitometry was determined by ImageLab 5. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values determined by one-way ANOVA Tukey’s multiple comparison test (B, C, F, H, G) or unpaired student T-test (E, I). * p<0.05, n.s: not significant.

Figure 2—figure supplement 1. STING1 activation in primary human cells and THP-1 cells reconstituted with WT human STING1.

(A). Total human Lung cells from WT/WT individuals were treated with indicated dose of diABZi for 24 hr. Cell death in CD4, CD8 T cells and CD19 B cells were determined by PI staining. (B). Sequencing results of human STING1 gene in WT/WT and WT/HAQ individuals. (C–D). STING1-KO THP-1 cells stably reconstituted with human WT (R232) were treated with indicated dose of diABZI for indicated time in culture. ISG-54 reporter luciferase activity was determined in cell supernatant and normalized to 10 ng/ml IFNβ-stimulated ISG-54 luciferase activity. Data are representative of at least two independent experiments. Graphs represent the mean with error bars indication s.e.m. p values determined by one-way ANOVA Tukey’s multiple comparison test. * p<0.05, n.s: not significant.

WT/HAQ human CD4 T cells are resistant to low doses of diABZI-induced cell death

WT/HAQ mouse splenocytes are resistant to low-dose diABZI-induced cell death (Figure 1G). To extend our observation into primary human T cells, we obtained lung explants from WT/WT and WT/HAQ individuals (Figure 2—figure supplement 1B) and treated them with diABZI in culture. 25 ng/ml diABZI killed WT/WT, but not WT/HAQ, human lung CD4 T cells (Figure 2C).

diABZI induces cell death in STING1-KO human THP-1 cells reconstituted with WT human STING1 (R232) but not HAQ, AQ or Q293 human STING1 allele

To further determine cell death influenced by human STING1 alleles HAQ, AQ, and Q293, we used the STING1-KO THP-1 cell line because STING1 agonist induces type I IFNs and cell death in STING1-KO THP-1 cells expressing WT human STING1 (Song et al., 2022; Figure 2—figure supplement 1C and D). We, thus, generated stable THP-1 STING1-KO lines expressing HAQ, AQ, WT, or Q293 STING1 allele. Cell death was determined by Annexin-V staining. diABZI killed THP-1 STING1-KO lines expressing WT but not HAQ, AQ, or Q293 STING1 allele (Figure 2D and E). No cell death was induced in the Q293 THP-1 cells stimulated by 20–200 ng/ml of diABZI (Figure 2F). diABZI also did not induce STING1 activation in Q293 THP-1 cells (Figure 2G). Notably, 50 ng/ml diABZI induced p-IRF3 activation and type I IFNs in AQ THP-1 cells but not HAQ THP-1 cells (Figure 2H and I), indicating that the STING1-cell death and STING1-IRF3-Type I IFNs pathways can be uncoupled.

HAQ and AQ alleles rescue the lymphopenia and suppress myeloid cell expansion in SAVI(N153S) mice

The in vivo significance of the STING1/MPYS-cell death is unclear. Furthermore, multiple cell death pathways, that is apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed (Murthy et al., 2020; Li et al., 2021; Song et al., 2022). The uncertainty likely results from studies using different cell types (primary cells vs cancer cell lines); species (human vs mouse); STING1 agonists (cGAMP, which requires cell permeabilization by detergents or lipid transfection, vs diABZi, DMXAA that can directly cross the membrane; Larkin et al., 2017; Cerboni et al., 2017; Gulen et al., 2017; Kabelitz et al., 2022; Wu et al., 2019). Critically, which mechanism is relevant in vivo, causing T cellpenia is not known. To clarify the in vivo significance and mechanisms of STING1-mediated cell death, we turned to SAVI mice.

SAVI is an autosomal dominant, inflammatory disease caused by one copy of a gain-of-function STING1 mutant (WT/SAVI) Liu et al., 2014). CD4 T cellpenia was found in SAVI patients and SAVI mouse models (Liu et al., 2014; Luksch et al., 2019. STING1 activation in SAVI mice is independent of ligands and happens in vivo. We thus generated HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice aiming to establish the in vivo significance and mechanism of STING1-cell death.

First, HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice had reduced splenomegaly compared to WT/SAVI(N153S) mice though their spleens were still larger than the littermates WT/HAQ and WT/AQ (Figure 3A and B). Next, HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice had similar spleen B cells and CD4 T cell numbers as the WT/HAQ, WT/AQ littermates (Figure 2B and C). Their CD8+ T cells were lower than their WT littermates but much higher than the WT/SAVI(N153S) mice (Figure 3D). Third, spleen myeloid cell numbers, that is neutrophils, Ly6Chi monocytes and F4/80 macrophages, were all reduced by half compared to WT/SAVI(N153S) mice (Figure 3E, H). Last, splenocytes from HAQ/SAVI, AQ/SAVI mice were partially resistant to diABZI, DMXAA-induced cell death ex vivo (Figure 3—figure supplement 1). Notably, the HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice also had restored bone marrow monocytes (Figure 4—figure supplement 1). Thus, HAQ and AQ alleles prevent lymphopenia and suppress myeloid cell expansion in SAVI(N153S) mice.

Figure 3. HAQ and AQ rescue the lymphopenia and suppress myeloid cell expansion in SAVI (N153S) mice.

(A) The size and weight of spleens from WT/HAQ, HAQ/SAVI, AQ/SAVI, WT/AQ, WT/SAVI. (B–D). Spleen CD19+ B cells, CD4, CD8 T cells were determined in the indicated mice by Flow. (E–H). Spleen Ly6G+ neutrophils, Ly6Chi monocytes and F4/80+ macrophage was determined in the indicated mice by Flow. Data are representative of three independent experiments. n=3–5 mice/group. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p<0.05, n.s: not significant.

Figure 3—figure supplement 1. Splenocytes from HAQ/SAVI, AQ/SAVI partially resist to STING1-activation-induced cell death ex vivo.

(A–B). Flow cytometry of HAQ/SAVI, AQ/SAVI, WT/WT or WT/HAQ splenocytes treated with diABZI (100 ng/ml) or DMXAA (20 µg/ml) for 24 hr. Cell death was determined by PI staining. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p<0.05. n.s: not significant.

Figure 3—figure supplement 2. HAQ and AQ restore bone marrow monocytes in SAVI (N153S) mice.

(A–D) Flow analysis of Ly6G+CD11B+ neutrophils and Ly6G-Ly6C+CD11B+ bone marrow monocytes from HAQ/SAVI, AQ/SAVI, WT/SAVI and their littermates. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p<0.05, n.s: not significant.

The HAQ allele alleviates and the AQ allele prevents SAVI(N153S) disease in mice

SAVI(N153S) disease is characterized by early onset, failure to thrive (low body weight), persistent lung inflammation, decreased lung function, and young death in humans and mouse models Liu et al., 2014; Frémond et al., 2021; Wu et al., 2019; Motwani et al., 2019. The HAQ/SAVI(N153S) mice weighed more and had an improved lifespan than the WT/SAVI(N153S) mice (Figure 4A and B). The lifespan, airway resistance, and tissue inflammation (lung, liver) were also improved in HAQ/SAVI(N153S) mice compared to the WT/SAVI(N153S) mice (Figure 4C, D, J and K). However, the pulmonary artery pressure was still elevated in HAQ/SAVI(N153S) mice (Figure 4E). Remarkably, the AQ/SAVI(N153S) mice had similar body weight and lifespan as the WT/AQ mice (Figure 4F and G). The airway resistance, pulmonary artery pressure, and tissue inflammation in AQ/SAVI(N153S) were similar to the WT/AQ littermates (Figure 4H, I, J and K). Thus, the HAQ allele alleviates and the AQ allele prevents inflammatory SAVI disease in mice. Interestingly, lungs from HAQ/SAVI, AQ/SAVI had similarly reduced infiltration of Ly6G+CD11B+ neutrophils and Ly6G-Ly6C+CD11B+ inflammatory monocytes compared to WT/SAVI mice (Figure 4—figure supplement 1).

Figure 4. HAQ and AQ alleles prevent SAVI(N153S) disease in mice.

(A, B, G) The size and body weight of HAQ/SAVI, AQ/SAVI, WT/SAVI and their littermates WT/HAQ, WT/AQ mice. (D, E, H, I). Airway resistance, and pulmonary artery pressure were determined as described in Materials and methods. (C, F). HAQ/SAVI, AQ/SAVI, WT/SAVI (10 mice/group), were monitored for survival by Kaplan-Meier. (J, K). Representative hematoxylin and eosin (H&E) staining of lung, liver sections from indicated mice. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p<0.05, **p<0.01. n.s.: not significant. (WBC): white blood cells; H: hepatocytes; K: Kupper cells; PV: portal vein; CV: central vein.

Figure 4—figure supplement 1. HAQ, AQ suppress lung myeloid cells infiltration in SAVI(N153S) mice.

(A–C) Flow analysis of lung Ly6G+CD11B+ neutrophils and Ly6G-Ly6C+CD11B+ monocytes from HAQ/SAVI, AQ/SAVI, WT/SAVI and their littermates WT/HAQ, WT/AQ mice. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p<0.05.

diABZI induces similar STING1, TBK1, IRF3, NFκB activation in the AQ/SAVI(N153S) and WT/SAVI(N153S) bone-marrow-derived-macrophage (BMDM)

SAVI was characterized as type I interferonopathy (Frémond et al., 2021). However, several studies showed that type I IFN signaling and IRF3 activation were dispensable for SAVI disease (Luksch et al., 2019; Stinson et al., 2022; Gao et al., 2022; Motwani et al., 2019). AQ allele prevents SAVI disease (Figure 4). However, diABZI-treated AQ/SAVI(N153S) and WT/SAVI(N153S) BMDM had similar TBK1-IRF3 activation and IFNβ production (Figure 5A and B). diABZI treatment caused IκBα degradation, and similar TNF production in WT/SAVI and AQ/SAVI BMDM (Figure 5C and D). Furthermore, diABZI activation led to STING1 protein degradation in WT/SAVI and AQ/SAVI BMDM (Figure 5E). Last, using cleavable crosslinker dithiobis succinimidyl propionate (DSP), we showed that STING1 in WT/SAVI, AQ/SAVI BMDM forms a similar dimer in situ (Figure 5F). Thus, the AQ/SAVI BMDM had similar STING1 degradation, TBK1, IRF3, NFκB activation, and dimerization as the WT/SAVI BMDM.

Figure 5. AQ/SAVI(N153S) cells had similar TBK1-IRF3, NFκB activation and STING1 degradation as the WT/SAVI(N153S) cells.

(A, C). BMDM from WT/WT, WT/SAVI, HAQ/SAVI and AQ/SAVI were treated with 100 ng/ml diABZi in culture for 2 hr. Cells were lysed and run on a 4~20% Mini-PROTEAN TGX Stain-Free Precast Gel. The blot was probed for phospho-Thr172-TBK1 antibody (CST, clone D52C2), phosphor-Ser 396-IRF3 (CST, clone 4D4G), STING1 (Proteintech, #19851–1-AP) and IκBα (CST, clone 44D4) antibody. (E). BMDM from WT/WT, WT/SAVI, HAQ/SAVI and AQ/SAVI were treated with 100 ng/ml diABZi in culture for 24 hr. Cells were lysed and run on a 4~20% Mini-PROTEAN TGX Stain-Free Precast Gel. The blot was probed for STING1 antibody (Proteintech, 19851–1-AP). (B, D). IFNβ and TNF were determined by ELISA in the cell supernatant from E. (F). BMDM from WT/WT, WT/SAVI, HAQ/SAVI and AQ/SAVI were treated with 400 µM cleavable chemical crosslinker DSP (Pierce, cat no: PG82081) in PBS for 1 hr at 4 °C. Cells were washed with PBS and lysed in RIPA buffer. Whole cell lysate was mixed with 4 x Laemmli Sample Buffer (BioRad, cat no 1610747) containing 5% 2-mercaptoethanol, heated at 95 °C for 10 min and, run on a 4~20% Mini-PROTEAN TGX Stain-Free Precast Gel. The blot was probed for STING1 antibody (Proteintech, 19851–1-AP). Densitometry was determined by ImageLab 5. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by unpaired student T-test (A–E) or one-way ANOVA Tukey’s multiple comparison test (D, B). * p<0.05, **p<0.01, ***p<0.001. n.s.: not significant; n.d: not detected.

The HAQ allele increased, and the AQ allele restored T-regs in SAVI(N153S) mice

IFNγ was proposed to drive SAVI disease (Stinson et al., 2022; Gao et al., 2022; Patel and Jin, 2019). We confirmed that WT/SAVI CD4 T cells were enriched with IFNγ+ cells (Figure 6A). However, WT/SAVI mice have CD4 T cellpenia. Thus, the total numbers of spleen IFNγ+ CD4 T cells were comparable in WT/SAVI and AQ/SAVI mice (Figure 6A). In contrast, the HAQ/SAVI mice had decreased IFNγ+ CD4 T cells (Figure 6A).

Figure 6. HAQ/SAVI(N153S) and AQ/SAVI(N153S) cells had 10-fold and 20-fold increased spleen T-regs compared to WT/SAVI mice.

(A) Flow cytometry analysis of IFNγ producing spleen CD4+ T cells from WT/HAQ, WT/AQ, WT/SAVI, HAQ/SAVI and AQ/SAVI mice. (B) Flow cytometry analysis of CD4+ FoxP3+ spleen T-regs. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p<0.05, **p<0.01, ***p<0.001. n.s.: not significant.

The induction of Foxp3 expression in T-reg cells during ongoing autoimmune inflammation resolved inflammation and pathology in mice (Hu et al., 2021). CD4 T cellpenia depletes CD4 T-regs. Indeed, WT/SAVI mice had ~20-fold reduction of spleen FoxP3+ T-regs compared to AQ/SAVI or WT/WT littermates (Figure 6B). The HAQ/SAVI mice also had ~10-fold more T-regs than the WT/SAVI littermate (Figure 6B).

Discussion

This study, using the HAQ, AQ, SAVI(N153S) Sting1 knock-in mice, reveals the in vivo significance and mechanism of STING1-mediated CD4 T cell death. HAQ, AQ alleles prevent CD4 T cellpenia, and increase/restore CD4 T-regs in SAVI mice. The results are consistent with previous finding that the impaired CD4 T cell proliferation by the SAVI(V155M) mutant could be rescued by the addition of the HAQ allele in vitro (Cerboni et al., 2017). STING1 has been increasingly implicated in inflammatory diseases such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cardiomyopathy, obesity, diabetes, neurodegenerative diseases, aging, and kidney injury, many of which are independent of type I IFNs (Skopelja-Gardner et al., 2022; Bai and Liu, 2021; Gao et al., 2023a). It is tempting to suggest that STING1 activation in CD4 T cells leads to CD4 T-regs depletion that break tissue tolerance and exacerbates tissue inflammation.

Human immunodeficiency virus (HIV) primarily infects CD4 T cells and might activate the STING1 pathway in CD4 T cells (Monroe et al., 2014; Doitsh et al., 2014; Jakobsen et al., 2015; Silvin and Manel, 2015; Altfeld and Gale, 2015; Krapp et al., 2018). The loss of CD4 T cells is the hallmark of untreated HIV infection Gubser et al., 2019; Morou et al., 2019, and the measurement of CD4 T cell count is a central part of HIV care. We found that HAQ and AQ CD4 T cells are resistant to STING1-mediated cell death. Mogensen and colleagues reported that HAQ/HAQ was enriched in HIV-infected long-term nonprogressors (Nissen et al., 2018). These HAQ/HAQ individuals had reduced inhibition of CD4 T cell proliferation and a reduced immune response to DNA and HIV (Nissen et al., 2018). It is likely that HIV infection activates STING1-cell death pathway in CD4 T cells. In HAQ/SAVI and AQ/SAVI mice, one copy of HAQ, AQ allele suppressed CD4 T cell death. HAQ, AQ carriers might have fewer HIV-induced CD4 T cell death, thus being long-term nonprogressors in HIV infection-induced Acquired immunodeficiency syndrome (AIDS; Nissen et al., 2018). Targeting STING1 to prevent CD4 T cell death might be a valid therapy for AIDS.

Activating the STING1 pathway is a promising strategy for cancer immunotherapy (Hines et al., 2023; Samson and Ablasser, 2022; Liu et al., 2021; Zheng et al., 2020; Corrales et al., 2015; Fu et al., 2015; Barber, 2011). Multiple STING1 agonists are in clinical trials (Meric-Bernstam et al., 2023; Meric-Bernstam et al., 2022). Recently, the safety issue emerged in some STING1 agonist trials (Meric-Bernstam et al., 2023; Meric-Bernstam et al., 2022). For example, in the STING1 agonist, ADU-S100, clinical trial, Grade 3/4 treatment-related adverse events were reported in 12.2% of 41 pretreated patients (NCT02675439) (Meric-Bernstam et al., 2023; Meric-Bernstam et al., 2022). The National Institutes of Health defines grade 3 as ‘incapacitating; unable to perform usual activities; requires absenteeism or bed rest.’ In a clinical trial using STING1 antibody-drug-conjugate (ADC) that conjugates diABZI to anti-HER2 Ab, a Grade 5 (fatal) serious adverse event was recorded and deemed related to the STING1-ADC (NCT05514717). SAVI disease, driven by overreacting STING1, is often fatal Liu et al., 2014. AQ, to a less degree, HAQ, suppress mortality in SAVI mice. Future STING1 clinical trials should be based on human STING1 genotype to achieve safe and effective responses.

Mechanistically, apoptosis, pyroptosis, ferroptosis, necroptosis, and PANoptosis have all been reported in STING1-mediated cell death (Kuhl et al., 2023; Jin et al., 2008; Gulen et al., 2017; Kabelitz et al., 2022; Murthy et al., 2020; Li et al., 2021; Song et al., 2022; Messaoud-Nacer et al., 2022; Tang et al., 2016). Different cell types and STING1 agonists used likely contributed to the inconsistency and complexity. Here, we focused on lymphopenia in the SAVI mice that avoids ligand-dependent, non-physiological dosage in STING1-mediated cell death. HAQ and AQ alleles could prevent CD4 T cellpenia in the SAVI mice strongly indicating that residue A230 or Q293 prevent STING1-mediated CD4 T cell death in vivo. Splenocyte from Q293 mice were resistant to STING1 agonists-induced cell death ex vivo. Thus, it is likely that the Q293 residue is critical for STING1-mediate lymphopenia. Notably, Q293 is outside the C-terminal tail (CTT) (residues 341–379 of human STING1) critical for TBK1 recruitment and IRF3 phosphorylation (Liu et al., 2015) or miniCTT domain (aa343–354) (Cerboni et al., 2017), or the UPR motif (aa322–343) (Wu et al., 2019) important for T cells death in vitro. Further studies are needed to understand how the aa293 of STING1 mediates cell death in vivo. Noteworthy, AQ/SAVI cells had similar TBK1-IRF3, NFκB activation and STING1 degradation as the WT/SAVI cells. Yet, AQ/SAVI mice did not have CD4 T cellpenia as WT/SAVI mice suggeSting1 that the canonical STING1-TBK1-IRF3/NFκB pathway, likely STING1 oligomerization, is not sufficient for the induction of cell death at the physiological condition.

We used the WT/N153S knock-in SAVI mouse model that spontaneously develop lung inflammation, T cell cytopenia, and early mortality, mimicking pathological findings in human SAVI patients (Warner et al., 2017). Using the WT/N153S SAVI mouse model and human Jurkat T cell line, it was proposed that STING1 activation causes chronic ER stress and unfolded protein response, leading to T cell death by apoptosis (Wu et al., 2019). Furthermore, the study showed that crossing WT/N153S mice to the OT-I mice reduced ER stress and restored CD8+, but not CD4+, T cells (Wu et al., 2019). The restoration of CD8+T cells reduces inflammation and lung disease (Wu et al., 2019). However, human WT/N154S SAVI patients have normal CD8+ T cells numbers (Liu et al., 2014), and primary human CD8+ T cells are largely resistant to STING1-agonists-induced cell death ex vivo (Figure 2A; Kuhl et al., 2023). Thus, it is puzzling how restoring CD8+ T cells can rescue SAVI phenotypes since the SAVI patients already have normal CD8+ T cells numbers.

Finally, it is unexpected that both HAQ and AQ alleles are resistant to cell death. Our previous studies showed that the HAQ and AQ alleles have opposite functions (Mansouri et al., 2022). AQ-STING1, not HAQ-STING1, responds to CDNs (Jin et al., 2011; Patel et al., 2017a; Mansouri et al., 2022; Sebastian et al., 2020; Yi et al., 2013; Patel et al., 2017b; Nissen et al., 2018; Ruiz-Moreno et al., 2018; Movert et al., 2023). AQ mice are lean while HAQ mice are fat (Mansouri et al., 2022). Most importantly, HAQ was positively selected, while AQ was negatively selected, in modern humans outside Africans (Mansouri et al., 2022). Thus, the death pathway of STING1 is also distinct from the STING1 function that was naturally selected. It is worth noting that the AQ allele does better than the HAQ allele in suppressing SAVI disease. Thus, besides preventing cell death, additional mechanism by the AQ allele, for example fatty acid metabolism (Mansouri et al., 2022; Vila et al., 2022), is involved in curing SAVI.

The limitations of the study

The poor transferability of mouse to humans is a major issue in STING1 research (Meric-Bernstam et al., 2023; Meric-Bernstam et al., 2022). The present study used AQ/SAVI and HAQ/SAVI mice. Confirmation is needed in humans with the identification and evaluation of people who are AQ/SAVI, HAQ/SAVI.

Materials and methods

Experimental design

The study was designed to reveal (i) the in vivo significance of the type I IFNs-independent, STING1-dependent cell death function; (ii) the interplay between common STING1 alleles HAQ, AQ and the rare, gain-of-function SAVI STING1 mutation; (iii) the driver for the inflammatory SAVI disease. Mouse splenocytes, primary human lung cells, human THP-1 cells and HAQ, AQ, SAVI knock-in mice were used to establish the in vivo significance and human relevance. All the repeats were biological replications that involve the same experimental procedures on different mice. Where possible, treatments were assigned blindly to the experimenter by another individual in the lab. When comparing samples from different groups, samples from each group were analyzed in concert, thereby preventing any biases that might arise from analyzing individual treatments on different days. All experiments were repeated at least twice.

Mice

WT/SAVI(N153S) mice were purchased from The Jackson Laboratory. HAQ, AQ mice were previously generated in the lab (Patel et al., 2017a; Mansouri et al., 2022). The Q293 mice were generated by Cyagen Biosciences. Briefly, the linearized targeting vector was transfected into JM8A3.N1 C57BL/6 N embryonic stem cells. A positive embryonic stem clone was subjected to the generation of chimera mice by injection using C57BL/6 J blastocysts as the host. Successful germline transmission was confirmed by PCR sequencing. The heterozygous mice were bred to Actin-flpase mice [The Jackson Laboratory, B6.Cg-Tg (ACTFLPe)9205Dym/J] to remove the neo gene and make the Q293 knock-in mouse. Age- and gender-matched mice (2–6 month old, both male and female) were used for indicated experiments. WT/SAVI (male) x WT/HAQ (female), WT/SAVI (male) x WT/AQ (female) breeders were set up to generate HAQ/SAVI, AQ/SAVI mice. Mice were housed at 22 °C under a 12‐hr light‐dark cycle with ad libitum access to water and a chow diet (3.1 kcal/g, Teklad 2018, Envigo, Sommerset, NJ) and bred under pathogen-free conditions in the Animal Research Facility at the University of Florida. Littermates of the same sex were randomly assigned to experimental groups. All mouse experiments were performed by the regulations and approval of the Institutional Animal Care and Use Committee at the University of Florida, IACUC202200000058.

Reagent

Recombinant human IFNβ (R&D, cat no. 8499-IF-010/CF), diABZI (Invivogen, cat no. 2138299-34-8), 2’3’-cGAMP (Invivogen, cat no. tlrl-nacga23-02), DMXAA (Invivogen, cat no. tlrl-dmx), H151 (Invivogen, cat no. inh-h151), RpRpSS-Cyclic di-AMP (Biolog, cat no. C118), THP1-Dual KO-STING1 Cells (Invivogen, cat no. thpd-kostg). All other chemical inhibitors are from Selleckchem. Mouse TNF alpha ELISA Ready Set Go. (eBioscience, cat no. 88–7324). Mouse IFN-Beta ELISA Kit (PBI, cat no. 42400).

Generation of THP-1 KO-STING1 cells stably expressing human STING1 alleles

THP1-Dual KO-STING1 cells were purchased from Invivogen (thpd-kostg). These cells are guaranteed mycoplasma-free and authenticated by the vendor. THP1-Dual KO-STING1 Cells in six-well plate were transfected with 1 µg STING1 plasmid (in pcDNA 3.1 vector) with Lipofectamine LTX and Plus Reagent (Invitrogen, cat no: A12621) according to the manufacturer’s instructions. Transfecting Plasmid DNA into THP-1 Cells Using Lipofectamine LTX Reagent | Thermo Fisher Scientific - US. Forty-eight hours after the transfection, the cell medium was changed. G418 (1 mg/ml) was added to the culture to select STING1 expressing THP-1 cells. The G418-resistant cells were established and expanded.

Histology

Lungs and livers were fixed in 10% formalin, paraffin-embedded, and cut into 4 µm sections. Lung, liver sections were then stained for hematoxylin-eosin. All staining procedures were performed by the histology core at the University of Florida. Briefly, tissue sectins were immersed Harris Hematoxylin for 10 s, then washed with tap water. Cleard sections were re-immersed in EOSIN stain for ~30 s. The sections were washed with tap water until clear, then dehydrate in ascending alcohol solutions (50%, 70%, 80%, 95% x 2, 100% x 2). Afterwards, the sections werer cleared with xylene (3–4 x). The sections were mounted on glass slide with permount organic mounting medium for visulization.

Lung function

Pulmonary function was evaluated using an isolated, buffer-perfused mouse lung apparatus (Hugo Sachs Elektronik, March-Huggstetten, Germany), as previously described (Cai et al., 2020). Briefly, mice were anesthetized with ketamine and xylazine and a tracheostomy was performed, and animals were ventilated with room air at 100 breaths/min at a tidal volume of 7 μl/g body weight with a positive end-expiratory pressure of 2 cm H2O using a pressure-controlled ventilator (Hugo Sachs Elektronik, March-Huggstetten, Germany).

Isolation of lung cells

Cells were isolated from the lung as previously described (Mansouri et al., 2020). The lungs were perfused with ice-cold PBS and removed. Lungs were digested in DMEM containing 200 μg/ml DNase I (Roche, 10104159001), 25 μg/ml Liberase TM (Roche, 05401119001) at 37 °C for 2 hr. Red blood cells were then lysed and a single-cell suspension was prepared by filtering through a 70 µm cell strainer.

BMDM activation

BMDMs were induced from mouse bone marrow cells cultured in RPMI 1640 (cat#11965; Invitrogen) with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES buffer, 1% nonessential amino acids, 50 mM 2-ME, 1% Pen/Strep, with 20 ng/ml M-CSF (Kingfisher, RP0407M) for 10 days (Patel et al., 2017a). STING1 agonists were added into the culture (no transfection or membrane permeabilization).

Flow cytometry

Single-cell suspensions were stained with fluorescent-dye-conjugated antibodies in PBS containing 2% FBS and 1 mM EDTA. Surface stains were performed at 4 °C for 20 min. For intracellular cytokine or transcription factor staining of murine and human cells, cells were fixed and permeabilized with the Foxp3 staining buffer set (eBioscience, cat no 00-5523-00). Cells were washed and stained with surface markers. Cells were then fixed and permeabilized (eBioscience, cat no. 00-5523-00) for intracellular cytokine stain. Data were acquired on a BD LSRFortessa and analyzed using the FlowJo software package (FlowJo, LLC). Cell sorting was performed on the BD FACSAriaIII Flow Cytometer and Cell Sorter.

Human lung explants

Human lung explants were procured at the Lung Transplant Center, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida. Donor and patients consent was obtained for a research protocol (UF IRB201902955-Treatment with IFNβ Induces Tolerogenic Lung Dendritic Cells in Human advanced lung disease). Healthy donor lungs were surgically removed postmortem, perfused, small pieces were cut from the right middle and lower lobes for research purpose, and stored in cold Perfadex at 4 °C for no more than 12 hr before processing. Ex planted lungs from emphysema lung transplant patients were stored in cold Perfadex at 4 °C for no more than 12 hr before the process. No lung explants were procured from prisoners.

Statistical analysis

To gain statistical power, we employ three ~four mice/groups to characterize lung immunity. Ten mice/group to monitor animal health. The statistical justification for group size was calculated using the SAS program to calculate the animal numbers. The analysis was carried out using a standard error of 0.5 for immunological assays, and a power of 0.9. All data are expressed as means ± SEM. Statistical significance was evaluated using Prism 9.0 software. Comparisons between two groups were analyzed by performing an unpaired Student’s t test. Comparisons between more than two groups were analyzed by performing a one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test.

Materials availability statement

The Q293 mouse is available upon request via a Material Transfer Agreement.

Funding Information

This paper was supported by the following grant:

http://dx.doi.org/10.13039/100000050 National Heart, Lung, and Blood Institute HL152163 to Lei Jin.

Acknowledgements

National Institutes of Health grant HL152163 (LJ).

Additional information

Competing interests

Author contributions

Ethics

Additional files

MDAR checklist

Data availability

Source data is deposited in Dryad https://doi.org/10.5061/dryad.m0cfxppcv.

The following dataset was generated:

Jin L 2024 Data from: The common TMEM173 HAQ, AQ alleles rescue CD4 T cellpenia, restore T-regs, and prevent SAVI (N153S) inflammatory disease in mice Dryad Digital Repository 10.5061/dryad.m0cfxppcv

10.7554/eLife.96790.3.sa0
eLife assessment
Rothlin Carla V Reviewing Editor Yale University United States

Incomplete
Useful
This study describes useful mouse models of knock-ins of human STING1 variants and an assessment of these variants' action in mouse immune cells. While the implications of the variants in the inflammatory response are of significant interest, limitations are still found in the authors' interpretation and conclusions made, and the evidence for the conclusion remains incomplete.

10.7554/eLife.96790.3.sa1
Reviewer #1 (Public Review):
Reviewer
Summary:

This manuscript by Aybar-Torres et al investigated the effect of common human STING1 variants on STING-mediated T cell phenotypes in mice. The authors previously made knock-in mice expressing human STING1 alleles HAQ or AQ, and here they established a new knock-in line Q293. The authors stimulated cells isolated from these mice with STING agonists and found that all three human mutant alleles resist cell death, leading to the conclusion that R293 residue is essential for STING-mediated cell death (there are several caveats with this conclusion, more below). The authors also bred HAQ and AQ alleles to the mouse Sting1-N153S SAVI mouse and observed varying levels of rescue of disease phenotypes with the AQ allele showing more complete rescue than the HAQ allele. The Q293 allele was not tested in the SAVI model. They conclude that the human common variants such as HAQ and AQ have a dominant negative effect over the gain-of-function SAVI mutants.

Strengths:

The authors and Dr. Jin's group previously made important observations of common human STING1 variants, and these knock-in mouse models are essential for understanding the physiological function of these alleles.

Weaknesses:

However, although some of the observations reported here are interesting, the data collectively does not support a unified model. The authors seem to be drawing two sets of conclusions from in vitro and in vivo experiments, and neither mechanism is clear. Several experiments need better controls, and these knock-in mice need more comprehensive functional characterization.

10.7554/eLife.96790.3.sa2
Reviewer #2 (Public Review):
Reviewer
Aybar-Torres and colleagues utilize common human STING alleles to dissect the mechanism of SAVI inflammatory disease. The authors demonstrate that these common alleles alleviate SAVI pathology in mice, and perhaps more importantly use the differing functionality of these alleles to provide insight into requirements of SAVI disease induction. Their findings suggest that it is residue A230 and/or Q293 that are required for SAVI induction, while the ability to induce an interferon-dependent inflammatory response is not. This is nicely exemplified by the AQ/SAVI mice that have an intact inflammatory response to STING activation, yet minimal disease progression. As both mutants seem to be resistant STING-dependent cell death, this manuscript also alludes to the importance of STING-dependent cell death, rather than STING-dependent inflammation, in the progression of SAVI pathology. I believe this manuscript makes some important connections between STING pathology mouse models and human genetics that would contribute to the field.

10.7554/eLife.96790.3.sa3
Author response
Aybar-Torres Alexandra a Author University of Florida Gainesville United States

Saldarriaga Lennon A Author The University of Florida Gainesville United States

Pham Ann t Author The University of Florida Gainesville United States

Emtiazjoo Amir m Author The University of Florida Gainesville United States

Sharma Ashish k Author The University of Florida Gainesville United States

Bryant Andrew j Author The University of Florida Gainesville United States

Jin Lei Author University of Florida Gainesville United States

The following is the authors’ response to the original reviews.

Summary Responses: Besides the WT allele, equivalent to the mouse TMEM173 gene, the human TMEM173 gene has two common alleles: the HAQ and AQ alleles carried by billions of people. The main conclusions and interpretation, summarized in the Title and Abstract, are (i) Different from the WT TMEM173 allele, the HAQ or AQ alleles are resistant to STING activation-induced cell death; (ii) STING residue 293 is critical for cell death; (iii) HAQ, AQ alleles are dominant to the SAVI allele; (iv) One copy of the AQ allele rescues the SAVI disease in mice. We propose that STING research and STING-targeting immunotherapy should consider human TMEM173 heterogeneity. These interpretations and conclusions were based on Data and Logic. We welcome alternative, logical interpretations and collaborations to advance the human TMEM173 research.

Public Reviews:

Reviewer #1 (Public Review):

Summary:

This manuscript by Aybar-Torres et al investigated the effect of common human STING1 variants on STING-mediated T cell phenotypes in mice. The authors previously made knock-in mice expressing human STING1 alleles HAQ or AQ, and here they established a new knock-in line Q293. The authors stimulated cells isolated from these mice with STING agonists and found that all three human mutant alleles resist cell death, leading to the conclusion that R293 residue is essential for STING-mediated cell death (there are several caveats with this conclusion, more below). The authors also bred HAQ and AQ alleles to the mouse Sting1-N153S SAVI mouse and observed varying levels of rescue of disease phenotypes with the AQ allele showing more complete rescue than the HAQ allele. The Q293 allele was not tested in the SAVI model. They conclude that the human common variants such as HAQ and AQ have a dominant negative effect over the gain-of-function SAVI mutants.

Strengths:

The authors and Dr. Jin's group previously made important observations of common human STING1 variants, and these knock-in mouse models are essential for understanding the physiological function of these alleles.

Weaknesses:

However, although some of the observations reported here are interesting, the data collectively does not support a unified model. The authors seem to be drawing two sets of conclusions from in vitro and in vivo experiments, and neither mechanism is clear. Several experiments need better controls, and these knock-in mice need more comprehensive functional characterization.

(1) In Figure 1, the authors are trying to show that STING agonist-induced splenocytes cell death is blocked by HAQ, AQ and Q alleles. The conclusion at line 134 should be splenocytes, not lymphocytes. Most experiments in this figure were done with mixed population that may involve cell-to-cell communication. Although TBK1-dependence is likely, a single inhibitor treatment of a mixed population is not sufficient to reach this conclusion.

We greatly appreciate Reviewer 1's insights. We changed the “lymphocytes” to “splenocytes” (line 133) as suggested. We respectfully disagree with Reviewer 1’s comments on TBK1. First, we used two different TBK1 inhibitors: BX795 and GSK8612. Second, because BX795 also inhibits PDK1, we used a PDK1 inhibitor GSK2334470; Third, both BX795 and GSK8612 completely inhibited diABZI-induced splenocyte cell death (Figure 1B) (lines 128 – 133). The logical conclusion is “TBK1 activation is required for STING-mediated mouse spleen cell death ex vivo”. (line 117).

Our discovery that the common human TMEM173 alleles are resistant to STING activation-induced cell death is a substantial finding. It further strengthens the argument that the HAQ and AQ alleles are functionally distinct from the WT allele 1-3. We wish to underscore the crucial message of this study-that 'STING research and STING-targeting immunotherapy should consider TMEM173 heterogeneity in humans' (line 37), which has been largely overlooked in current STING clinical trials 4.

Regarding STING-Cell death, as we stated in the Introduction (lines 65-77). (i) STING-mediated cell death is cell type-dependent 5-7 and type I IFNs-independent 5,7,8. (ii) The in vivo biological significance of STING-mediated cell death is not clear 7,8. (iii) The mechanisms of STING-Cell death remain controversial. Multiple cell death pathways, i.e., apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed 7,9,10. SAVI/HAQ, SAVI/AQ prevented lymphopenia and alleviated SAVI disease in mice. Thus, the manuscript provides some answers to the biological significance of STING-cell death in vivo, which is new. Regarding the molecular mechanism, splenocytes from Q293/Q293 mice are resistant to STING cell death. The logical conclusion is that the amino acid 293 is critical for STING cell death (line 29).

Extensive studies are needed, beyond the scope of this manuscript, on how aa293 and TBK1 mediates STING-Cell death to resolve the controversies in the STING-cell death fields (e.g. apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis).

(2) Q293 knock-in mouse needs to be characterized and compared to HAQ and AQ. Is this mutant expressed in tissues? Does this mutant still produce IFN and other STING activities? Does the protein expression level altered on Western blot? Is the mutant protein trafficking affected? In the authors' previous publications and some of the Western blot here, expression levels of each of these human STING1 protein in mice are drastically different. HAQ and AQ also have different effects on metabolism (pmid: 36261171), which could complicate interoperation of the T cell phenotypes.

These are very important questions that require rigorous investigations that are beyond the scope of this manuscript. This manuscript, titled “The common TMEM173 HAQ, AQ alleles rescue CD4 T cellpenia, restore T-regs, and prevent SAVI (N153S) inflammatory disease in mice” does not focus on Q293 mice. We have been investigating the common human TMEM173 alleles since 2011 from the discovery 11 , mouse model 1,3, human clinical trial 2, and human genetics studies 3. This manuscript is another step towards understanding these common human TMEM173 alleles with the new discovery that HAQ, AQ alleles are resistant to STING cell death.

(3) HAQ/WT and AQ/WT splenocytes are protected from STING agonist-induced cell death equally well (Figure 1G). HAQ/SAVI shows less rescue compared to AQ/SAVI. These are interesting observations, but mechanism is unclear and not clearly discussed. E.g., how does AQ protect disease pathology better than HAQ (that contains AQ)? Does Q293 allele also fully rescue SAVI?

In this manuscript, Figure 6 shows AQ/SAVI had more T-regs than HAQ/SAVI (lines 251 – 261). In our previous publication on HAQ, AQ knockin mice, we showed that AQ T-regs have more IL-10 than HAQ T-regs 3. Thus, increased IL-10+ Tregs in AQ mice may contribute to an improved phenotype in AQ/SAVI compared to HAQ/SAVI. However, we are not excluding other contributions (e.g. metabolic difference) (lines 332-335). We are exploring these possibilities.

(4) Figure 2 feels out of place. First of all, why are the authors using human explant lung tissues? PBMCs should be a better source for lymphocytes. In untreated conditions, both CD4 and B cells show ~30% dying cells, but CD8 cells show 0% dying cells. This calls for technical concerns on the CD8 T cell property or gating strategy because in the mouse experiment (Figure 1A) all primary lymphocytes show ~30% cell death at steady-state. Second, Figure 2C, these type of partial effect needs multiple human donors to confirm. Three, the reconstitution of THP1 cells seems out of place. STING-mediated cell death mechanism in myeloid and lymphoid cells are likely different. If the authors want to demonstrate cell death in myeloid cells using THP1, then these reconstituted cell lines need to be better validated. Expression, IFN signaling, etc. The parental THP1 cells is HAQ/HAQ, how does that compare to the reconstitutions? There are published studies showing THP1-STING-KO cells reconstituted with human variants do not respond to STING agonists as expected. The authors need to be scientifically rigorous on validation and caution on their interpretations.

Figure 2 is necessary because it reveals the difference between mouse and human STING cell death, which is critical to understand STING in human health and diseases (lines 160-161). Figure 2A-2B showed that STING activation killed human CD4 T cells, but not human CD8 T cells or B cells. This observation is different from Figure 1A, where STING activation killed mouse CD4, CD8 T cells, and CD19 B cells, revealing the species-specific STING cell death responses. Regarding human CD8 T cells, as we stated in the Discussion (lines 323-325), human CD8 T cells (PBMC) are not as susceptible as the CD4 T cells to STING-induced cell death 8. We used lung lymphocytes that showed similar observations (Figure 2A). For Figure 2C, we used 2 WT/HAQ and 3 WT/WT individuals (lines 738-739). We generate HAQ, AQ THP-1 cells in STING-KO THP-1 cells (Invivogen,, cat no. thpd-kostg) (lines 380-387).

A recent study found that a new STING agonist SHR1032 induces cell death in STING-KO THP-1 cells expressing WT(R232) human STING 10 (line 182). SHR1032 suppressed THP1-STING-WT(R232) cell growth at GI50: 23 nM while in the parental THP1-STING-HAQ cells, the GI50 of SHR1032 was >103 nM 10. Cytarabine was used as an internal control where SHR1032 killed more robustly than cytarabine in the THP1-STING-WT(R232) cells but much less efficiently than cytarabine in the THP-1-STING-HAQ cells 10.

Our manuscript rigorously uses mouse splenocytes, human lung lymphocytes, THP-1 reconstituted with HAQ, AQ, and HAQ/SAVI, AQ/SAVI mice, to demonstrate that the common human HAQ, AQ alleles are resistant to STING cell death in vitro and in vivo.

We agree with Reviewer 1 that STING-mediated cell death mechanisms in myeloid and lymphoid cells may be different and likely contribute to the different mechanisms proposed in STING cell death research 7,9,10. Our study focuses on the in vivo STING-mediated T cellpenia.

(5) Figure 2G, H, I are confusing. AQ is more active in producing IFN signaling than HAQ and Q is the least active. How to explain this?

We stated in the Introduction that “AQ responds to CDNs and produce type I IFNs in vivo and in vitro 3,12,13 ”(line 92-93). We reported that the AQ knock in mice responded to STING activation 3. We previously showed that there was a negative natural selection on the AQ allele in individuals outside of Africa 3. 28% of Africans are WT/AQ but only 0.6% East Asians are WT/AQ 3. In contrast, the HAQ allele was positively selected in non-Africans 3. Investigation to understand the mechanisms and biological significance of these naturally selected human TMEM173 alleles has been ongoing in the lab.

(6) The overall model is unclear. If HAQ, AQ and Q are loss-of-function alleles and Q is the key residue for STING-mediated cell death, then why AQ is the most active in producing IFN signaling and AQ/SAVI rescues disease most completely? If these human variants act as dominant negatives, which would be consistent with the WT/het data, then how do you explain AQ is more dominant negative than HAQ?

In this manuscript, Figure 6 shows AQ/SAVI had more T-regs than HAQ/SAVI (lines 251 – 261). In our previous publication on HAQ, AQ knockin mice, we showed that AQ T-regs have more IL-10 and mitochondria activity than HAQ T-regs 3. Nevertheless, we are not excluding other contributions (e.g. metabolic difference) by the AQ allele (lines 332-335). Last, we used modern human evolution to discover the dominance of these common human STING alleles. In modern humans outside Africans, HAQ was positively selected while AQ was negatively selected 3. However, AQ is likely dominant to HAQ because there is no HAQ/AQ individuals outside Africa. The genetic dominance of common human TMEM173 allele is a new concept. More investigation is ongoing.

(7) As a general note, SAVI disease phenotypes involve multiple cell types. Lymphocyte cell death is only one of them. The authors' characterization of SAVI pathology is limited and did not analyze immunopathology of the lung.

Both radioresistant parenchymal and/or stromal cells and hematopoietic cells influence SAVI pathology in mice 14,15. Nevertheless, the lack of CD 4 T cells, including the anti-inflammatory T-regs, likely contributes to the inflammation in SAVI mice and patients 16. We characterized lung function, lung inflammation (Figure 4), lung neutrophils, and inflammatory monocyte infiltration (Figure S5) (lines 232-235).

(8) Line 281, the discussion on HIV T cell death mechanism is not relevant and over-stretching. This study did not evaluate viral infection in T cells at all. The original finding of HAQ/HAQ enrichment in HIV/AIDS was 2/11 in LTNP vs 0/11 in control, arguably not the strongest statistics.

Several publications have linked STING to HIV pathogenesis 17-22 (line 271). CD4 T cellpenia is a hallmark of AIDS. The manuscript studies STING activation-induced T cellpenia in vivo. It is not stretching to ask, for example, does preventing STING T cell death (e.g HAQ, AQ alleles) can restore CD4 T cell counts and improve care for AIDS patients?

Reviewer #2 (Public Review):

Aybar-Torres and colleagues utilize common human STING alleles to dissect the mechanism of SAVI inflammatory disease. The authors demonstrate that these common alleles alleviate SAVI pathology in mice, and perhaps more importantly use the differing functionality of these alleles to provide insight into requirements of SAVI disease induction. Their findings suggest that it is residue A230 and/or Q293 that are required for SAVI induction, while the ability to induce an interferon-dependent inflammatory response is not. This is nicely exemplified by the AQ/SAVI mice that have an intact inflammatory response to STING activation, yet minimal disease progression. As both mutants seem to be resistant STING-dependent cell death, this manuscript also alludes to the importance of STING-dependent cell death, rather than STING-dependent inflammation, in the progression of SAVI pathology. While I have some concerns, I believe this manuscript makes some important connections between STING pathology mouse models and human genetics that would contribute to the field.

Some points to consider:

(1) While the CD4+ T cell counts from HAQ/SAVI and AQ/SAVI mice suggest that these T cells are protected from STING-dependent cell death, an assay that explores this more directly would strengthen the manuscript. This is also supported by Fig 2C, but I believe a strength of this manuscript is the comparison between the two alleles. Therefore, if possible, I would recommend the isolation of T cells from these mice and direct stimulation with diABZI or other STING agonist with a cell death readout.

Please see the new Figure S3 for cell death by diABZI, DMXAA in Splenocytes from WT/WT, WT/HAQ, HAQ/SAVI, AQ/SAVI mice. The HAQ/SAVI and AQ/SAVI splenocytes showed similar partial resistance to STING activation-induced cell death (lines 214-216).

(2) Related to the above point - further exemplifying that the Q293 locus is essential to disease, even in human cells, would also strengthen the paper. It seems that CD4 T cell loss is a major component of human SAVI. While not co_mpletely necessary, repeating the THP1 cell death experiments from Fig 2 with a human T cell line would round out the study nicely._

We examined HAQ, AQ mouse splenocytes, HAQ human lung lymphocytes, THP-1 reconstituted with HAQ, AQ, and HAQ/SAVI, AQ/SAVI mice, to demonstrate that the common human HAQ, AQ alleles are resistant to STING cell death in vitro and in vivo. Additional human T cell line work does not add too much. We hope to conduct more human PBMC or lung lymphocytes STING cell death experiments from HAQ, AQ individuals as we continue the human STING alleles investigation.

(3) While I found the myeloid cell counts and BMDM data interesting, I think some more context is needed to fully loop this data into the story. Is myeloid cell expansion exemplified by SAVI patients? Do we know if myeloid cells are the major contributors to the inflammation these patients experience? Why should the SAVI community care about the Q293 locus in myeloid cells?

This is likely a misunderstanding. We use BMDM for the purpose of comparing STING signaling (TBK1, IRF3, NFkB, STING activation) by WT/SAVI, HAQ/SAVI, AQ/SAVI. Ideally, we would like to compare STING signaling in CD4 T cells from WT/SAVI to HAQ/SAVI, AQ/SAVI mice. However, WT/SAVI has no CD4 T cells. Doing so, we are making the assumption that the basic STING signaling (TBK1, IRF3, NFkB, STING activation) is conserved between T cells and macrophages.

(4) The functional assays in Figure 4 are exciting and really connect the alleles to disease progression. To strengthen the manuscript and connect all the data, I would recommend additional readouts from these mice that address the inflammatory phenotype shown in vitro in Figure 5. For example, measuring cytokines from these mice via ELISA or perhaps even Western blots looking for NFkB or STING activation would be supportive of the story. This would also allow for some tissue specificity. I believe looking for evidence of inflammation and STING activation in the lungs of these mice, for example, would further connect the data to human SAVI pathology.

Reviewer 2 suggests looking for evidence of inflammation and STING activation in the lungs of HAQ/SAVI, AQ/SAVI. We would like to elaborate further. First, anti-inflammatory treatments, e.g. steroids, DMARDs, IVIG, Etanercept (TNF), rituximab, Nifedipine, amlodipine, et al., all failed in SAVI patients 23. JAK inhibitors on SAVI had mixed outcomes (lines 55-58). Second, Figure S5 examined lung neutrophils and inflammatory monocyte infiltration. Interestingly, while AQ/SAVI mice had a better lung function than HAQ/SAVI mice (Figure 4D, 4E vs 4H, 4I), HAQ/SAVI and AQ/SAVI lungs had comparable neutrophils and inflammatory monocyte infiltration (Figure S5). Last, SAVI is classified as type I interferonopathy 23, but the lung diseases of SAVI are mainly independent of type I IFNs 24-27. The AQ allele suppresses SAVI in vivo. Understanding the mechanisms by which AQ rescues SAVI may lead to curative care for SAVI patients.

Recommendations for the authors:

Reviewer #1 (Recommendations For The Authors):

One suggestion is to streamline this study by focusing on STING-mediated cell death only in CD4 T cells. The authors can use in vitro PBMC isolated human T cells, ex vivo T cells from the knock-in mice, and in vivo T cells from the SAVI breeding. The current manuscript includes myeloid cell death, Tregs, complex SAVI disease pathology, which is too confusing and too complex to explain with the varying effect from the three human STING1 variants.

We sincerely appreciate Reviewer 1’s suggestion. The goal of our human STING alleles research has always been translational, i.e. improving human health. Even as a monogenetic disease, the SAVI pathology is still complex. For example, thought as a type I Interferonopathy, SAVI is largely independent of type I IFNs. Similarly, STING-activation-induced cell death, while contribute to SAVI, is not the whole story, as the Reviewer pointed out in the Comment 3 & 6 &7. HAQ/SAVI mice still died early and had lung dysfunction (Figure 4). In contrast, AQ/SAVI mice restore lifespan and lung function. We had Figure 6 show different T-regs between AQ/SAVI and HAQ/SAVI mice. In addition, AQ mice had more IL-10+ T-regs than HAQ mice 3. Therefore, we are excited about developing AQ-based curative therapy for SAVI patients (preventing cell death and inducing immune tolerance). Again, we thank the Reviewer for the suggestion. Additional research is ongoing.

Reviewer #2 (Recommendations For The Authors):

Minor points

(1) Generation of THP1 cells with the human STING alleles is missing from methods.

We added the protocol in the methods (lines 380-387). THP-1 KO line stable expressing WT STING was first described by Weikang Tao’s group 10.

(2) Some abbreviations are not expanded (CDA).

CDA is expanded as cyclic di-AMP (e.g. line 375).

References.

(1) Patel, S. et al. The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele. J Immunol 198, 776-787 (2017).

(2) Sebastian, M. et al. Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy. JCI Insight 5 (2020).

(3) Mansouri, S. et al. MPYS Modulates Fatty Acid Metabolism and Immune Tolerance at Homeostasis Independent of Type I IFNs. J Immunol 209, 2114-2132 (2022).

(4) Sivick, K. E. et al. Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele". J Immunol 198, 4183-4185 (2017).

(5) Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat Commun 8, 427 (2017).

(6) Kabelitz, D. et al. Signal strength of STING activation determines cytokine plasticity and cell death in human monocytes. Sci Rep 12, 17827 (2022).

(7) Murthy, A. M. V., Robinson, N. & Kumar, S. Crosstalk between cGAS-STING signaling and cell death. Cell Death Differ 27, 2989-3003 (2020).

(8) Kuhl, N. et al. STING agonism turns human T cells into interferon-producing cells but impedes their functionality. EMBO Rep 24, e55536 (2023).

(9) Li, C., Liu, J., Hou, W., Kang, R. & Tang, D. STING1 Promotes Ferroptosis Through MFN1/2-Dependent Mitochondrial Fusion. Front Cell Dev Biol 9, 698679 (2021).

(10) Song, C. et al. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis. Sci Rep 12, 8579 (2022).

(11) Jin, L. et al. Identification and characterization of a loss-of-function human MPYS variant. Genes Immun 12, 263-269 (2011).

(12) Yi, G. et al. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One 8, e77846 (2013).

(13) Patel, S. et al. Response to Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele". J Immunol 198, 4185-4188 (2017).

(14) Gao, K. M. et al. Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration. Cell Rep 43, 114114 (2024).

(15) Gao, K. M., Motwani, M., Tedder, T., Marshak-Rothstein, A. & Fitzgerald, K. A. Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNgamma-dependent mortality in STING gain-of-function mice. Proc Natl Acad Sci U S A 119, e2202327119 (2022).

(16) Hu, W. et al. Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunity. Nat Immunol 22, 1163-1174 (2021).

(17) Monroe, K. M. et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 343, 428-432 (2014).

(18) Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509-514 (2014).

(19) Jakobsen, M. R., Olagnier, D. & Hiscott, J. Innate immune sensing of HIV-1 infection. Curr Opin HIV AIDS 10, 96-102 (2015).

(20) Silvin, A. & Manel, N. Innate immune sensing of HIV infection. Curr Opin Immunol 32, 54-60 (2015).

(21) Altfeld, M. & Gale, M., Jr. Innate immunity against HIV-1 infection. Nat Immunol 16, 554-562 (2015).

(22) Krapp, C., Jonsson, K. & Jakobsen, M. R. STING dependent sensing - Does HIV actually care? Cytokine Growth Factor Rev 40, 68-76 (2018).

(23) Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371, 507-518 (2014).

(24) Luksch, H. et al. STING-associated lung disease in mice relies on T cells but not type I interferon. J Allergy Clin Immunol 144, 254-266 e258 (2019).

(25) Stinson, W. A. et al. The IFN-gamma receptor promotes immune dysregulation and disease in STING gain-of-function mice. JCI Insight 7 (2022).

(26) Warner, J. D. et al. STING-associated vasculopathy develops independently of IRF3 in mice. J Exp Med 214, 3279-3292 (2017).

(27) Fremond, M. L. et al. Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. J Allergy Clin Immunol Pract 9, 803-818 e811 (2021).

No competing interests declared.

Data curation, Formal analysis, Investigation, Methodology.

Data curation, Formal analysis, Investigation, Methodology.

Data curation, Formal analysis, Investigation, Methodology.

Resources, Methodology.

Data curation, Formal analysis, Investigation, Writing – review and editing.

Data curation, Formal analysis, Supervision, Investigation, Writing – review and editing.

Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Project administration, Writing – review and editing.

The donor lung and data are from deceased individuals. The specimens or data are de-identified for the purpose of this study. Under these conditions, the human study is exempt from Federal regulation, under category 4 (E4) Human lung explants were procured at the Lung Transplant Center, Division of Pulmonary,Critical Care and Sleep Medicine, Department of Medicine, University of Florida. Donor and patients consent was obtained for a research protocol (UF IRB201902955-Treatment with IFNs; Induces Tolerogenic Lung Dendritic Cells in Human advanced lung disease).

All mouse experiments were performed by the regulations and approval of the Institutional Animal Care and Use Committee at the University of Florida, IACUC202200000058.
==== Refs
References

Altfeld M Gale M 2015 Innate immunity against HIV-1 infection Nature Immunology 16 554 562 10.1038/ni.3157 25988887
Bai J Liu F 2021 cGAS‒STING signaling and function in metabolism and kidney diseases Journal of Molecular Cell Biology 13 728 738 10.1093/jmcb/mjab066 34665236
Barber GN 2011 Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses Current Opinion in Immunology 23 10 20 10.1016/j.coi.2010.12.015 21239155
Barber GN 2015 STING: infection, inflammation and cancer Nature Reviews. Immunology 15 760 770 10.1038/nri3921 26603901
Cai J Gehrau R Tu Z Leroy V Su G Shang J Mas VR Emtiazjoo A Pelaez A Atkinson C Machuca T Upchurch GR Sharma AK 2020 MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells The Journal of Heart and Lung Transplantation 39 1476 1490 10.1016/j.healun.2020.09.012 33067103
Cerboni S Jeremiah N Gentili M Gehrmann U Conrad C Stolzenberg MC Picard C Neven B Fischer A Amigorena S Rieux-Laucat F Manel N 2017 Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes The Journal of Experimental Medicine 214 1769 1785 10.1084/jem.20161674 28484079
Corrales L Glickman LH McWhirter SM Kanne DB Sivick KE Katibah GE Woo SR Lemmens E Banda T Leong JJ Metchette K Dubensky TW Gajewski TF 2015 Direct Activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity Cell Reports 11 1018 1030 10.1016/j.celrep.2015.04.031 25959818
Dai Y Liu X Zhao Z He J Yin Q 2020 Stimulator of interferon genes-associated vasculopathy with onset in infancy: a systematic review of case reports Frontiers in Pediatrics 8 577918 10.3389/fped.2020.577918 33425809
Doitsh G Galloway NLK Geng X Yang Z Monroe KM Zepeda O Hunt PW Hatano H Sowinski S Muñoz-Arias I Greene WC 2014 Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection Nature 505 509 514 10.1038/nature12940 24356306
Frémond M-L Hadchouel A Berteloot L Melki I Bresson V Barnabei L Jeremiah N Belot A Bondet V Brocq O Chan D Dagher R Dubus J-C Duffy D Feuillet-Soummer S Fusaro M Gattorno M Insalaco A Jeziorski E Kitabayashi N Lopez-Corbeto M Mazingue F Morren M-A Rice GI Rivière JG Seabra L Sirvente J Soler-Palacin P Stremler-Le Bel N Thouvenin G Thumerelle C Van Aerde E Volpi S Willcocks S Wouters C Breton S Molina T Bader-Meunier B Moshous D Fischer A Blanche S Rieux-Laucat F Crow YJ Neven B 2021 Overview of STING-associated vasculopathy with onset in infancy (SAVI) Among 21 Patients The Journal of Allergy and Clinical Immunology 9 803 818 10.1016/j.jaip.2020.11.007 33217613
Fu J Kanne DB Leong M Glickman LH McWhirter SM Lemmens E Mechette K Leong JJ Lauer P Liu W Sivick KE Zeng Q Soares KC Zheng L Portnoy DA Woodward JJ Pardoll DM Dubensky TW Kim Y 2015 STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade Science Translational Medicine 7 283ra252 10.1126/scitranslmed.aaa4306 25877890
Gao KM Motwani M Tedder T Marshak-Rothstein A Fitzgerald KA 2022 Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNγ-dependent mortality in STING gain-of-function mice PNAS 119 e2202327119 10.1073/pnas.2202327119 35696583
Gao KM Marshak-Rothstein A Fitzgerald KA 2023a Type-1 interferon-dependent and -independent mechanisms in cyclic GMP-AMP synthase-stimulator of interferon genes-driven auto-inflammation Current Opinion in Immunology 80 102280 10.1016/j.coi.2022.102280 36638547
Gao L Zhang J Yang T Jiang L Liu X Wang S Wang X Huang Y Wang H Zhang M Gong T Ma L Li C He C Meng X Wu Y 2023b STING/ACSL4 axis-dependent ferroptosis and inflammation promote hypertension-associated chronic kidney disease Molecular Therapy 31 3084 3103 10.1016/j.ymthe.2023.07.026 37533255
Gao KM Chiang K Jiang Z Korkmaz FT Janardhan HP Trivedi CM Quinton LJ Gingras S Fitzgerald KA Marshak-Rothstein A 2024 Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration Cell Reports 43 114114 10.1016/j.celrep.2024.114114 38625791
Gubser C Pitman MC Lewin SR 2019 CD4+ T cell signatures in HIV infection Nature Immunology 20 948 950 10.1038/s41590-019-0447-5 31308542
Gulen MF Koch U Haag SM Schuler F Apetoh L Villunger A Radtke F Ablasser A 2017 Signalling strength determines proapoptotic functions of STING Nature Communications 8 427 10.1038/s41467-017-00573-w 28874664
Gulen MF Samson N Keller A Schwabenland M Liu C Glück S Thacker VV Favre L Mangeat B Kroese LJ Krimpenfort P Prinz M Ablasser A 2023 cGAS-STING drives ageing-related inflammation and neurodegeneration Nature 620 374 380 10.1038/s41586-023-06373-1 37532932
Hines JB Kacew AJ Sweis RF 2023 The Development of STING agonists and emerging results as a cancer immunotherapy Current Oncology Reports 25 189 199 10.1007/s11912-023-01361-0 36705879
Hu W Wang ZM Feng Y Schizas M Hoyos BE Veeken J Verter JG Bou-Puerto R Rudensky AY 2021 Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunity Nat Immunol 22 1163 1174 34426690
Jakobsen MR Olagnier D Hiscott J 2015 Innate immune sensing of HIV-1 infection Current Opinion in HIV and AIDS 10 96 102 10.1097/COH.0000000000000129 25485569
Jin L Waterman PM Jonscher KR Short CM Reisdorph NA Cambier JC 2008 MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals Molecular and Cellular Biology 28 5014 5026 10.1128/MCB.00640-08 18559423
Jin L Xu LG Yang IV Davidson EJ Schwartz DA Wurfel MM Cambier JC 2011 Identification and characterization of a loss-of-function human MPYS variant Genes and Immunity 12 263 269 10.1038/gene.2010.75 21248775
Jin L Getahun A Knowles HM Mogan J Akerlund LJ Packard TA Perraud AL Cambier JC 2013 STING/MPYS mediates host defense against Listeria monocytogenes infection by regulating Ly6C(hi) monocyte migration Journal of Immunology 190 2835 2843 10.4049/jimmunol.1201788 23378430
Kabelitz D Zarobkiewicz M Heib M Serrano R Kunz M Chitadze G Adam D Peters C 2022 Signal strength of STING activation determines cytokine plasticity and cell death in human monocytes Scientific Reports 12 17827 10.1038/s41598-022-20519-7 36280676
Kim D Song KB Choi EJ Yu J 2022 A 17-year-old girl diagnosed with sting-associated vasculopathy with onset in infancy (SAVI) after lung transplantation Chest 162 e249 e252 10.1016/j.chest.2022.05.025 36344133
Krapp C Jønsson K Jakobsen MR 2018 STING dependent sensing - Does HIV actually care? Cytokine & Growth Factor Reviews 40 68 76 10.1016/j.cytogfr.2018.03.002 29548644
Kuhl N Linder A Philipp N Nixdorf D Fischer H Veth S Kuut G Xu TT Theurich S Carell T Subklewe M Hornung V 2023 STING agonism turns human T cells into interferon-producing cells but impedes their functionality EMBO Reports 24 e55536 10.15252/embr.202255536 36705069
Larkin B Ilyukha V Sorokin M Buzdin A Vannier E Poltorak A 2017 Cutting edge: activation of STING in T cells induces type I IFN responses and cell death Journal of Immunology 199 397 402 10.4049/jimmunol.1601999 28615418
Li C Liu J Hou W Kang R Tang D 2021 STING1 promotes ferroptosis through MFN1/2-dependent mitochondrial fusion Frontiers in Cell and Developmental Biology 9 698679 10.3389/fcell.2021.698679 34195205
Li H Guo X Aquino E Wu C 2023 Mini review: STING activation during non-alcoholic fatty liver disease Frontiers in Nutrition 10 1139339 10.3389/fnut.2023.1139339 36937350
Liu Y Jesus AA Marrero B Yang D Ramsey SE Montealegre Sanchez GA Tenbrock K Wittkowski H Jones OY Kuehn HS Lee C-CR DiMattia MA Cowen EW Gonzalez B Palmer I DiGiovanna JJ Biancotto A Kim H Tsai WL Trier AM Huang Y Stone DL Hill S Kim HJ St. Hilaire C Gurprasad S Plass N Chapelle D Horkayne-Szakaly I Foell D Barysenka A Candotti F Holland SM Hughes JD Mehmet H Issekutz AC Raffeld M McElwee J Fontana JR Minniti CP Moir S Kastner DL Gadina M Steven AC Wingfield PT Brooks SR Rosenzweig SD Fleisher TA Deng Z Boehm M Paller AS Goldbach-Mansky R 2014 Activated STING in a vascular and pulmonary syndrome New England Journal of Medicine 371 507 518 10.1056/NEJMoa1312625 25029335
Liu S Cai X Wu J Cong Q Chen X Li T Du F Ren J Wu YT Grishin NV Chen ZJ 2015 Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation Science 347 aaa2630 10.1126/science.aaa2630 25636800
Liu Y Lu X Qin N Qiao Y Xing S Liu W Feng F Liu Z Sun H 2021 STING, A promising target for small molecular immune modulator: A review European Journal of Medicinal Chemistry 211 113113 10.1016/j.ejmech.2020.113113 33360799
Luksch H Stinson WA Platt DJ Qian W Kalugotla G Miner CA Bennion BG Gerbaulet A Rösen-Wolff A Miner JJ 2019 STING-associated lung disease in mice relies on T cells but not type I interferon The Journal of Allergy and Clinical Immunology 144 254 266 10.1016/j.jaci.2019.01.044 30772497
Mansouri S Katikaneni DS Gogoi H Pipkin M Machuca TN Emtiazjoo AM Jin L 2020 Lung IFNAR1hi TNFR2+ cDC2 promotes lung regulatory T cells induction and maintains lung mucosal tolerance at steady state Mucosal Immunology 13 595 608 10.1038/s41385-020-0254-1 31959883
Mansouri S Gogoi H Patel S Katikaneni DS Singh A Aybar-Torres A de Lartigue G Jin L 2022 MPYS modulates fatty acid metabolism and immune tolerance at homeostasis independent of type I IFNs Journal of Immunology 209 2114 2132 10.4049/jimmunol.2200158 36261171
Meric-Bernstam F Sweis RF Hodi FS Messersmith WA Andtbacka RHI Ingham M Lewis N Chen X Pelletier M Chen X Wu J McWhirter SM Müller T Nair N Luke JJ 2022 Phase I dose-escalation trial of MIW815 (ADU-S100), an Intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas Clinical Cancer Research 28 677 688 10.1158/1078-0432.CCR-21-1963 34716197
Meric-Bernstam F Sweis RF Kasper S Hamid O Bhatia S Dummer R Stradella A Long GV Spreafico A Shimizu T Steeghs N Luke JJ McWhirter SM Müller T Nair N Lewis N Chen X Bean A Kattenhorn L Pelletier M Sandhu S 2023 Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study Clinical Cancer Research 29 110 121 10.1158/1078-0432.CCR-22-2235 36282874
Messaoud-Nacer Y Culerier E Rose S Maillet I Rouxel N Briault S Ryffel B Quesniaux VFJ Togbe D 2022 STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS) Cell Death & Disease 13 269 10.1038/s41419-022-04664-5 35338116
Monroe KM Yang Z Johnson JR Geng X Doitsh G Krogan NJ Greene WC 2014 IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV Science 343 428 432 10.1126/science.1243640 24356113
Morou A Brunet-Ratnasingham E Dubé M Charlebois R Mercier E Darko S Brassard N Nganou-Makamdop K Arumugam S Gendron-Lepage G Yang L Niessl J Baxter AE Billingsley JM Rajakumar PA Lefebvre F Johnson RP Tremblay C Routy J-P Wyatt RT Finzi A Douek DC Kaufmann DE 2019 Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease Nature Immunology 20 1059 1070 10.1038/s41590-019-0418-x 31308541
Motwani M Pawaria S Bernier J Moses S Henry K Fang T Burkly L Marshak-Rothstein A Fitzgerald KA 2019 Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models PNAS 116 7941 7950 10.1073/pnas.1818281116 30944222
Movert E Bolarin JS Valfridsson C Velarde J Skrede S Nekludov M Hyldegaard O Arnell P Svensson M Norrby-Teglund A Cho KH Elhaik E Wessels MR Råberg L Carlsson F 2023 Interplay between human STING genotype and bacterial NADase activity regulates inter-individual disease variability Nature Communications 14 4008 10.1038/s41467-023-39771-0 37414832
Murthy AMV Robinson N Kumar S 2020 Crosstalk between cGAS-STING signaling and cell death Cell Death and Differentiation 27 2989 3003 10.1038/s41418-020-00624-8 32948836
Nissen SK Pedersen JG Helleberg M Kjær K Thavachelvam K Obel N Tolstrup M Jakobsen MR Mogensen TH 2018 Multiple homozygous variants in the STING-encoding TMEM173 Gene in HIV long-term nonprogressors Journal of Immunology 200 3372 3382 10.4049/jimmunol.1701284 29632140
Patel S Blaauboer SM Tucker HR Mansouri S Ruiz-Moreno JS Hamann L Schumann RR Opitz B Jin L 2017a The Common R71H-G230A-R293Q human TMEM173 is a null allele Journal of Immunology 198 776 787 10.4049/jimmunol.1601585 27927967
Patel S Blaauboer SM Tucker HR Mansouri S Ruiz-Moreno JS Hamann L Schumann RR Opitz B Jin L 2017b Response to comment on “the common R71H-G230A-R293Q Human TMEM173 is a null allele.” Journal of Immunology 198 4185 4188 10.4049/jimmunol.1700322 28533277
Patel S Jin L 2019 TMEM173 variants and potential importance to human biology and disease Genes and Immunity 20 82 89 10.1038/s41435-018-0029-9 29728611
Pham AT Oliveira AC Albanna M Alvarez-Castanon J Dupee Z Patel D Fu C Mukhsinova L Nguyen A Jin L Bryant AJ 2024 Non-interferon-dependent role of STING signaling in pulmonary hypertension Arteriosclerosis, Thrombosis, and Vascular Biology 44 124 142 10.1161/ATVBAHA.123.320121 37942608
Picard C Thouvenin G Kannengiesser C Dubus J-C Jeremiah N Rieux-Laucat F Crestani B Belot A Thivolet-Béjui F Secq V Ménard C Reynaud-Gaubert M Reix P 2016 Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 Mutation) Chest 150 e65 e71 10.1016/j.chest.2016.02.682 27613991
Ramanjulu JM Pesiridis GS Yang J Concha N Singhaus R Zhang S-Y Tran J-L Moore P Lehmann S Eberl HC Muelbaier M Schneck JL Clemens J Adam M Mehlmann J Romano J Morales A Kang J Leister L Graybill TL Charnley AK Ye G Nevins N Behnia K Wolf AI Kasparcova V Nurse K Wang L Puhl AC Li Y Klein M Hopson CB Guss J Bantscheff M Bergamini G Reilly MA Lian Y Duffy KJ Adams J Foley KP Gough PJ Marquis RW Smothers J Hoos A Bertin J 2018 Design of amidobenzimidazole STING receptor agonists with systemic activity Nature 564 439 443 10.1038/s41586-018-0705-y 30405246
Ruiz-Moreno JS Hamann L Shah JA Verbon A Mockenhaupt FP Puzianowska-Kuznicka M Naujoks J Sander LE Witzenrath M Cambier JC Suttorp N Schumann RR Jin L Hawn TR Opitz B CAPNETZ Study Group 2018 The common HAQ STING variant impairs cGAS-dependent antibacterial responses and is associated with susceptibility to Legionnaires’ disease in humans PLOS Pathogens 14 e1006829 10.1371/journal.ppat.1006829 29298342
Samson N Ablasser A 2022 The cGAS-STING pathway and cancer Nature Cancer 3 1452 1463 10.1038/s43018-022-00468-w 36510011
Sebastian M Hsiao CJ Futch HS Eisinger RS Dumeny L Patel S Gobena M Katikaneni DS Cohen J Carpenter AM Spiryda L Heldermon CD Jin L Brantly ML 2020 Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy JCI Insight 5 e136141 10.1172/jci.insight.136141 32376795
Silvin A Manel N 2015 Innate immune sensing of HIV infection Current Opinion in Immunology 32 54 60 10.1016/j.coi.2014.12.003 25617674
Skopelja-Gardner S An J Elkon KB 2022 Role of the cGAS-STING pathway in systemic and organ-specific diseases Nature Reviews. Nephrology 18 558 572 10.1038/s41581-022-00589-6 35732833
Song C Liu D Liu S Li D Horecny I Zhang X Li P Chen L Miller M Chowdhury R Issa M Shen R Yan Y Zhang F Zhang L Zhang L Bai C Feng J Zhuang L Zhang R Li J Wilkinson H Liu J Tao W 2022 SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis Scientific Reports 12 8579 10.1038/s41598-022-12449-1 35595822
Stinson WA Miner CA Zhao FR Lundgren AJ Poddar S Miner JJ 2022 The IFN-γ receptor promotes immune dysregulation and disease in STING gain-of-function mice JCI Insight 7 e155250 10.1172/jci.insight.155250 36073546
Szego EM Malz L Bernhardt N Rösen-Wolff A Falkenburger BH Luksch H 2022 Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice eLife 11 e81943 10.7554/eLife.81943 36314770
Tang C-HA Zundell JA Ranatunga S Lin C Nefedova Y Del Valle JR Hu C-CA 2016 Agonist-mediated activation of sting induces apoptosis in malignant B Cells Cancer Research 76 2137 2152 10.1158/0008-5472.CAN-15-1885 26951929
Tang X Xu H Zhou C Peng Y Liu H Liu J Li H Yang H Zhao S 2020 STING-associated vasculopathy with onset in infancy in three children with new clinical aspect and unsatisfactory therapeutic responses to Tofacitinib Journal of Clinical Immunology 40 114 122 10.1007/s10875-019-00690-9 31705453
Vila IK Chamma H Steer A Saccas M Taffoni C Turtoi E Reinert LS Hussain S Marines J Jin L Bonnefont X Hubert M Schwartz O Paludan SR Van Simaeys G Doumont G Sobhian B Vlachakis D Turtoi A Laguette N 2022 STING orchestrates the crosstalk between polyunsaturated fatty acid metabolism and inflammatory responses Cell Metabolism 34 125 139 10.1016/j.cmet.2021.12.007 34986331
Volpi S Insalaco A Caorsi R Santori E Messia V Sacco O Terheggen-Lagro S Cardinale F Scarselli A Pastorino C Moneta G Cangemi G Passarelli C Ricci M Girosi D Derchi M Bocca P Diociaiuti A El Hachem M Cancrini C Tomà P Granata C Ravelli A Candotti F Picco P DeBenedetti F Gattorno M 2019 efficacy and adverse events during janus kinase inhibitor treatment of SAVI syndrome Journal of Clinical Immunology 39 476 485 10.1007/s10875-019-00645-0 31144250
Warner JD Irizarry-Caro RA Bennion BG Ai TL Smith AM Miner CA Sakai T Gonugunta VK Wu J Platt DJ Yan N Miner JJ 2017 STING-associated vasculopathy develops independently of IRF3 in mice The Journal of Experimental Medicine 214 3279 3292 10.1084/jem.20171351 28951494
Wu J Chen YJ Dobbs N Sakai T Liou J Miner JJ Yan N 2019 STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death The Journal of Experimental Medicine 216 867 883 10.1084/jem.20182192 30886058
Wu J Dobbs N Yang K Yan N 2020 Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion Immunity 53 115 126 10.1016/j.immuni.2020.06.009 32640258
Yamashiro LH Wilson SC Morrison HM Karalis V Chung J-YJ Chen KJ Bateup HS Szpara ML Lee AY Cox JS Vance RE 2020 Interferon-independent STING signaling promotes resistance to HSV-1 in vivo Nature Communications 11 3382 10.1038/s41467-020-17156-x 32636381
Yan M Li Y Luo Q Zeng W Shao X Li L Wang Q Wang D Zhang Y Diao H Rong X Bai Y Guo J 2022 Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice Cell Death Discovery 8 258 10.1038/s41420-022-01046-w 35538059
Yi G Brendel VP Shu C Li P Palanathan S Cheng Kao C 2013 Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides PLOS ONE 8 e77846 10.1371/journal.pone.0077846 24204993
Zheng J Mo J Zhu T Zhuo W Yi Y Hu S Yin J Zhang W Zhou H Liu Z 2020 Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy Molecular Cancer 19 133 10.1186/s12943-020-01250-1 32854711
